Efficacy and Safety of Alogliptin in Subjects With Type 2 Diabetes

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Takeda
ClinicalTrials.gov Identifier:
NCT00286455
First received: February 1, 2006
Last updated: February 1, 2012
Last verified: February 2012
Results First Received: June 8, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Diabetes Mellitus
Interventions: Drug: Alogliptin
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Participants enrolled at 117 investigative sites in 16 countries from 24 February 2006 to 05 July 2007.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Participants with a historical diagnosis of type 2 diabetes mellitus were enrolled in one of 3, once-daily (QD) treatment groups.

Reporting Groups
  Description
Placebo QD Alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.
Alogliptin 12.5 mg QD Alogliptin 12.5 mg, tablets, orally, once daily for up to 26 weeks.
Alogliptin 25 mg QD Alogliptin 25 mg, tablets, orally, once daily for up to 26 weeks.

Participant Flow:   Overall Study
    Placebo QD     Alogliptin 12.5 mg QD     Alogliptin 25 mg QD  
STARTED     65     133     131  
COMPLETED     40     105     107  
NOT COMPLETED     25     28     24  
Hyperglycemia rescue                 19                 13                 10  
Adverse Event                 1                 3                 2  
Lost to Follow-up                 0                 3                 3  
Physician Decision                 3                 0                 2  
Protocol Violation                 1                 1                 0  
Participant Non-compliance                 1                 0                 0  
Withdrawal by Subject                 0                 8                 7  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Placebo QD Alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.
Alogliptin 12.5 mg QD Alogliptin 12.5 mg, tablets, orally, once daily for up to 26 weeks.
Alogliptin 25 mg QD Alogliptin 25 mg, tablets, orally, once daily for up to 26 weeks.
Total Total of all reporting groups

Baseline Measures
    Placebo QD     Alogliptin 12.5 mg QD     Alogliptin 25 mg QD     Total  
Number of Participants  
[units: participants]
  65     133     131     329  
Age, Customized  
[units: participants]
       
<65 years     53     110     111     274  
Between 65 and 74 years     8     18     16     42  
≥75 years     4     5     4     13  
Gender  
[units: participants]
       
Female     32     68     54     154  
Male     33     65     77     175  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26.   [ Time Frame: Baseline and Week 26. ]

2.  Secondary:   Change From Baseline in Glycosylated Hemoglobin (Week 4).   [ Time Frame: Baseline and Week 4. ]

3.  Secondary:   Change From Baseline in Glycosylated Hemoglobin (Week 8).   [ Time Frame: Baseline and Week 8. ]

4.  Secondary:   Change From Baseline in Glycosylated Hemoglobin (Week 12).   [ Time Frame: Baseline and Week 12. ]

5.  Secondary:   Change From Baseline in Glycosylated Hemoglobin (Week 16).   [ Time Frame: Baseline and Week 16. ]

6.  Secondary:   Change From Baseline in Glycosylated Hemoglobin (Week 20).   [ Time Frame: Baseline and Week 20. ]

7.  Secondary:   Change From Baseline in Fasting Plasma Glucose (Week 1).   [ Time Frame: Baseline and Week 1. ]

8.  Secondary:   Change From Baseline in Fasting Plasma Glucose (Week 2).   [ Time Frame: Baseline and Week 2. ]

9.  Secondary:   Change From Baseline in Fasting Plasma Glucose (Week 4).   [ Time Frame: Baseline and Week 4. ]

10.  Secondary:   Change From Baseline in Fasting Plasma Glucose (Week 8).   [ Time Frame: Baseline and Week 8. ]

11.  Secondary:   Change From Baseline in Fasting Plasma Glucose (Week 12).   [ Time Frame: Baseline and Week 12. ]

12.  Secondary:   Change From Baseline in Fasting Plasma Glucose (Week 16).   [ Time Frame: Baseline and Week 16. ]

13.  Secondary:   Change From Baseline in Fasting Plasma Glucose (Week 20).   [ Time Frame: Baseline and Week 20. ]

14.  Secondary:   Change From Baseline in Fasting Plasma Glucose (Week 26).   [ Time Frame: Baseline and Week 26. ]

15.  Secondary:   Number of Participants With Marked Hyperglycemia (Fasting Plasma Glucose ≥ 200 mg Per dL).   [ Time Frame: 26 Weeks. ]

16.  Secondary:   Number of Participants Requiring Rescue.   [ Time Frame: 26 Weeks. ]

17.  Secondary:   Change From Baseline in Fasting Proinsulin (Week 4).   [ Time Frame: Baseline and Week 4. ]

18.  Secondary:   Change From Baseline in Fasting Proinsulin (Week 8).   [ Time Frame: Baseline and Week 8. ]

19.  Secondary:   Change From Baseline in Fasting Proinsulin (Week 12).   [ Time Frame: Baseline and Week 12. ]

20.  Secondary:   Change From Baseline in Fasting Proinsulin (Week 16).   [ Time Frame: Baseline and Week 16. ]

21.  Secondary:   Change From Baseline in Fasting Proinsulin (Week 20).   [ Time Frame: Baseline and Week 20. ]

22.  Secondary:   Change From Baseline in Fasting Proinsulin (Week 26).   [ Time Frame: Baseline and Week 26. ]

23.  Secondary:   Change From Baseline in Insulin (Week 4).   [ Time Frame: Baseline and Week 4. ]

24.  Secondary:   Change From Baseline in Insulin (Week 8).   [ Time Frame: Baseline and Week 8. ]

25.  Secondary:   Change From Baseline in Insulin (Week 12).   [ Time Frame: Baseline and Week 12. ]

26.  Secondary:   Change From Baseline in Insulin (Week 16).   [ Time Frame: Baseline and Week 16. ]

27.  Secondary:   Change From Baseline in Insulin (Week 20).   [ Time Frame: Baseline and Week 20. ]

28.  Secondary:   Change From Baseline in Insulin (Week 26).   [ Time Frame: Baseline and Week 26. ]

29.  Secondary:   Change From Baseline in Proinsulin/Insulin Ratio (Week 4).   [ Time Frame: Baseline and Week 4. ]

30.  Secondary:   Change From Baseline in Proinsulin/Insulin Ratio (Week 8).   [ Time Frame: Baseline and Week 8. ]

31.  Secondary:   Change From Baseline in Proinsulin/Insulin Ratio (Week 12).   [ Time Frame: Baseline and Week 12. ]

32.  Secondary:   Change From Baseline in Proinsulin/Insulin Ratio (Week 16).   [ Time Frame: Baseline and Week 16. ]

33.  Secondary:   Change From Baseline in Proinsulin/Insulin Ratio (Week 20).   [ Time Frame: Baseline and Week 20. ]

34.  Secondary:   Change From Baseline in Proinsulin/Insulin Ratio (Week 26).   [ Time Frame: Baseline and Week 26. ]

35.  Secondary:   Change From Baseline in C-peptide (Week 4).   [ Time Frame: Baseline and Week 4. ]

36.  Secondary:   Change From Baseline in C-peptide (Week 8).   [ Time Frame: Baseline and Week 8. ]

37.  Secondary:   Change From Baseline in C-peptide (Week 12).   [ Time Frame: Baseline and Week 12. ]

38.  Secondary:   Change From Baseline in C-peptide (Week 16).   [ Time Frame: Baseline and Week 16. ]

39.  Secondary:   Change From Baseline in C-peptide (Week 20).   [ Time Frame: Baseline and Week 20. ]

40.  Secondary:   Change From Baseline in C-peptide (Week 26).   [ Time Frame: Baseline and Week 26. ]

41.  Secondary:   Number of Participants With Glycosylated Hemoglobin ≤ 6.5%.   [ Time Frame: Baseline and Week 26. ]

42.  Secondary:   Number of Participants With Glycosylated Hemoglobin ≤ 7.0%.   [ Time Frame: Baseline and Week 26. ]

43.  Secondary:   Number of Participants With Glycosylated Hemoglobin ≤ 7.5%.   [ Time Frame: Baseline and Week 26. ]

44.  Secondary:   Number of Participants With Glycosylated Hemoglobin Decrease From Baseline ≥ 0.5%.   [ Time Frame: Baseline and Week 26. ]

45.  Secondary:   Number of Participants With Glycosylated Hemoglobin Decrease From Baseline ≥ 1.0%.   [ Time Frame: Baseline and Week 26. ]

46.  Secondary:   Number of Participants With Glycosylated Hemoglobin Decrease From Baseline ≥ 1.5%.   [ Time Frame: Baseline and Week 26. ]

47.  Secondary:   Number of Participants With Glycosylated Hemoglobin Decrease From Baseline ≥ 2.0%.   [ Time Frame: Baseline and Week 26. ]

48.  Secondary:   Change From Baseline in Body Weight (Week 8).   [ Time Frame: Baseline and Week 8. ]

49.  Secondary:   Change From Baseline in Body Weight (Week 12).   [ Time Frame: Baseline and Week 12. ]

50.  Secondary:   Change From Baseline in Body Weight (Week 20).   [ Time Frame: Baseline and Week 20. ]

51.  Secondary:   Change From Baseline in Body Weight (Week 26).   [ Time Frame: Baseline and Week 26. ]

52.  Secondary:   Change From Baseline in Glucagon (Week 4).   [ Time Frame: Baseline and Week 4. ]

53.  Secondary:   Change From Baseline in Glucagon (Week 8).   [ Time Frame: Baseline and Week 8. ]

54.  Secondary:   Change From Baseline in Glucagon (Week 12).   [ Time Frame: Baseline and Week 12. ]

55.  Secondary:   Change From Baseline in Glucagon (Week 16).   [ Time Frame: Baseline and Week 16. ]

56.  Secondary:   Change From Baseline in Glucagon (Week 20).   [ Time Frame: Baseline and Week 20. ]

57.  Secondary:   Change From Baseline in Glucagon (Week 26).   [ Time Frame: Baseline and Week 26. ]


  Serious Adverse Events


  Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Sr. VP, Clinical Science
Organization: Takeda Global Research and Development Center, Inc.
phone: 800-778-2860
e-mail: clinicaltrialregistry@tpna.com


Publications of Results:

Responsible Party: Takeda
ClinicalTrials.gov Identifier: NCT00286455     History of Changes
Other Study ID Numbers: SYR-322-PLC-010, 2005-004670-24, U1111-1113-8462
Study First Received: February 1, 2006
Results First Received: June 8, 2011
Last Updated: February 1, 2012
Health Authority: United States: Food and Drug Administration